Targeting CCR4 as an emerging strategy for cancer therapy and vaccines

被引：36
|
作者：
Bayry, Jagadeesh [1 ,2 ,3 ]
Tartour, Eric [4 ,5 ]
Tough, David F. [6 ]
机构：
[1] Inst Nacl Sante Rech Med, Unite 1138, F-75006 Paris, France
[2] Univ Paris 06, Ctr Rech Cordeliers, F-75006 Paris 6, France
[3] Univ Paris 05, UMR S 1138 Paris, F-75006 Paris, France
[4] Univ Paris 05, PARCC, Unite 970, Inst Natl Sante Rech Med, F-75015 Paris, France
[5] Hop Europeen Georges Pompidou, Serv Immunol Biol, AP HP, F-75015 Paris, France
[6] GlaxoSmithKline Med Discovery Ctr, Innmunoinflammat Therapeut Area, Epinova Discovery Performance Unit, Stevenage SG1 2NY, Herts, England
来源：
TRENDS IN PHARMACOLOGICAL SCIENCES | 2014年 / 35卷 / 04期
关键词：
REGULATORY T-CELLS; SURVIVAL; LYMPHOMA; ANTIBODY;
D O I：
10.1016/j.tips.2014.02.003
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：163 / 165
页数：3
相关论文
共 50 条
  • [31] CCR4 and its ligands: from bench to bedside
    Yoshie, Osamu
    Matsushima, Kouji
    INTERNATIONAL IMMUNOLOGY, 2015, 27 (01) : 11 - 20
  • [32] Synthesis of spirolactams and spiropiperidines as CCR4 receptor antagonists
    Hansen, JD
    Newhouse, BJ
    Allen, S
    Anderson, A
    Eary, T
    Schiro, J
    Gaudino, J
    Laird, E
    Allen, AC
    Chantry, D
    Eberhardt, C
    Burgess, LE
    TETRAHEDRON LETTERS, 2006, 47 (01) : 69 - 72
  • [33] Targeting CCR4 with mogamulizumab in refractory CD3-CD4+ lymphocytic-variant hypereosinophilic syndrome
    Ledoult, Emmanuel
    Groh, Matthieu
    Meresse, Bertrand
    Dubois, Romain
    Trauet, Jacques
    Toussaint, Elise
    Delbeke, Marie
    Hachulla, Eric
    Terriou, Louis
    De Masson, Adele
    Vasseur, Michele
    Labalette, Myriam
    Launay, David
    Kahn, Jean -Emmanuel
    Lefevre, Guillaume
    HAEMATOLOGICA, 2024, 109 (06) : 1984 - 1988
  • [34] The abnormal expression of CCR4 and CCR6 on Tregs in rheumatoid arthritis
    Li, Ning
    Wei, Wei
    Yin, Feng
    Chen, Maogen
    Ma, Tian R.
    Wu, Qiang
    Zhou, Jie R.
    Zheng, Song-Guo
    Han, Jie
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2015, 8 (09): : 15043 - 15053
  • [35] RNA deadenylation by CCR4–NOT controls heart function
    Alexandra Le Bras
    Nature Reviews Cardiology, 2018, 15 : 197 - 197
  • [36] The chemokine receptor CCR4 promotes tumor growth and lung metastasis in breast cancer
    Ji-Yu Li
    Zhou-Luo Ou
    San-Jian Yu
    Xiao-Li Gu
    Chen Yang
    Ao-Xiang Chen
    Gen-Hong Di
    Zhen-Zhou Shen
    Zhi-Ming Shao
    Breast Cancer Research and Treatment, 2012, 131 : 837 - 848
  • [37] Discovery and SAR of trisubstituted thiazolidinones as CCR4 antagonists
    Allen, S
    Newhouse, B
    Anderson, AS
    Fauber, B
    Allen, A
    Chantry, D
    Eberhardt, C
    Odingo, J
    Burgess, LE
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (07) : 1619 - 1624
  • [38] Structure and assembly of the NOT module of the human CCR4–NOT complex
    Andreas Boland
    Ying Chen
    Tobias Raisch
    Stefanie Jonas
    Duygu Kuzuoğlu-Öztürk
    Lara Wohlbold
    Oliver Weichenrieder
    Elisa Izaurralde
    Nature Structural & Molecular Biology, 2013, 20 : 1289 - 1297
  • [39] Trametinib improves Treg selectivity of α-CCR4 mAb by regulating CCR4 expression in CTLs induced via TCR/TGF-β signaling
    Ono, Shoya
    Suzuki, Susumu
    Kondo, Yutaro
    Goto, Mitsuo
    Ogawa, Tetsuya
    Ito, Hideaki
    Takahara, Taishi
    Satou, Akira
    Tsuzuki, Toyonori
    Yoshikawa, Kazuhiro
    Nagao, Toru
    Ueda, Ryuzo
    CANCER SCIENCE, 2023, 114 : 2062 - 2062
  • [40] CCR4 is a key modulator of innate immune responses
    Ness, Traci L.
    Ewing, Jillian L.
    Hogaboam, Cory M.
    Kunkel, Steven L.
    JOURNAL OF IMMUNOLOGY, 2006, 177 (11): : 7531 - 7539
12345